Document is current
Any future updates will be listed below
-
Authors
Wang, Qinghua
Jiang, Fan
Xu, Yulong
Lei, Yuyang
Zhang, Li
Sun, Xiaodong
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04994288 at ClinicalTrials.govDocuments that mention this clinical trial
Population Pharmacokinetics of Efsubaglutide Alfa in Healthy Subjects and Subjects with Type 2 Diabetes
https://doi.org/10.1007/s40262-025-01475-7
Exposure–Response Analysis of Efsubaglutide Alfa in Patients with Type 2 Diabetes Mellitus
https://doi.org/10.1007/s40262-025-01570-9
-
Funding
Funding for this research was provided by:
This study was sponsored by Shanghai Innogen Pharmaceutical Technology Co., Ltd.
- License Information
-
More Information
Article History
Received: 6 March 2025
Accepted: 14 August 2025
First Online: 17 October 2025
Declarations
:
: QW is the founder and actual controller of Innogen Pharmaceutical Co. Ltd. FJ and YX are employees of the company. All the remaining authors declare no competing interests.
: All data are available upon reasonable request. Data will be made available upon reasonable request, subject to the protection of research participants’ privacy.
: YX and LZ drafted the manuscript. YX, YL, and FJ analyzed the data and produced the figures. QW and XS reviewed and edited the manuscript.
: All studies included in this analysis were approved by the relevant ethics committees and conducted in accordance with the principles of the Declaration of Helsinki and the International Council for Harmonisation guidelines for Good Clinical Practice (ICH-GCP).
: The model codes that support the findings of this study are accessible upon reasonable request by contacting the corresponding author.
: Not applicable.
: Written, informed consent was obtained from all participants.
